Cargando…

The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania

Endemicity mapping is required to determining whether a district requires mass drug administration (MDA). Current guidelines for mapping LF require that two sites be selected per district and within each site a convenience sample of 100 adults be tested for antigenemia or microfilaremia. One or more...

Descripción completa

Detalles Bibliográficos
Autores principales: Gass, Katherine M., Sime, Heven, Mwingira, Upendo J., Nshala, Andreas, Chikawe, Maria, Pelletreau, Sonia, Barbre, Kira A., Deming, Michael S., Rebollo, Maria P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643143/
https://www.ncbi.nlm.nih.gov/pubmed/28976981
http://dx.doi.org/10.1371/journal.pntd.0005944
_version_ 1783271477681848320
author Gass, Katherine M.
Sime, Heven
Mwingira, Upendo J.
Nshala, Andreas
Chikawe, Maria
Pelletreau, Sonia
Barbre, Kira A.
Deming, Michael S.
Rebollo, Maria P.
author_facet Gass, Katherine M.
Sime, Heven
Mwingira, Upendo J.
Nshala, Andreas
Chikawe, Maria
Pelletreau, Sonia
Barbre, Kira A.
Deming, Michael S.
Rebollo, Maria P.
author_sort Gass, Katherine M.
collection PubMed
description Endemicity mapping is required to determining whether a district requires mass drug administration (MDA). Current guidelines for mapping LF require that two sites be selected per district and within each site a convenience sample of 100 adults be tested for antigenemia or microfilaremia. One or more confirmed positive tests in either site is interpreted as an indicator of potential transmission, prompting MDA at the district-level. While this mapping strategy has worked well in high-prevalence settings, imperfect diagnostics and the transmission potential of a single positive adult have raised concerns about the strategy’s use in low-prevalence settings. In response to these limitations, a statistically rigorous confirmatory mapping strategy was designed as a complement to the current strategy when LF endemicity is uncertain. Under the new strategy, schools are selected by either systematic or cluster sampling, depending on population size, and within each selected school, children 9–14 years are sampled systematically. All selected children are tested and the number of positive results is compared against a critical value to determine, with known probabilities of error, whether the average prevalence of LF infection is likely below a threshold of 2%. This confirmatory mapping strategy was applied to 45 districts in Ethiopia and 10 in Tanzania, where initial mapping results were considered uncertain. In 42 Ethiopian districts, and all 10 of the Tanzanian districts, the number of antigenemic children was below the critical cutoff, suggesting that these districts do not require MDA. Only three Ethiopian districts exceeded the critical cutoff of positive results. Whereas the current World Health Organization guidelines would have recommended MDA in all 55 districts, the present results suggest that only three of these districts requires MDA. By avoiding unnecessary MDA in 52 districts, the confirmatory mapping strategy is estimated to have saved a total of $9,293,219.
format Online
Article
Text
id pubmed-5643143
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56431432017-10-30 The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania Gass, Katherine M. Sime, Heven Mwingira, Upendo J. Nshala, Andreas Chikawe, Maria Pelletreau, Sonia Barbre, Kira A. Deming, Michael S. Rebollo, Maria P. PLoS Negl Trop Dis Research Article Endemicity mapping is required to determining whether a district requires mass drug administration (MDA). Current guidelines for mapping LF require that two sites be selected per district and within each site a convenience sample of 100 adults be tested for antigenemia or microfilaremia. One or more confirmed positive tests in either site is interpreted as an indicator of potential transmission, prompting MDA at the district-level. While this mapping strategy has worked well in high-prevalence settings, imperfect diagnostics and the transmission potential of a single positive adult have raised concerns about the strategy’s use in low-prevalence settings. In response to these limitations, a statistically rigorous confirmatory mapping strategy was designed as a complement to the current strategy when LF endemicity is uncertain. Under the new strategy, schools are selected by either systematic or cluster sampling, depending on population size, and within each selected school, children 9–14 years are sampled systematically. All selected children are tested and the number of positive results is compared against a critical value to determine, with known probabilities of error, whether the average prevalence of LF infection is likely below a threshold of 2%. This confirmatory mapping strategy was applied to 45 districts in Ethiopia and 10 in Tanzania, where initial mapping results were considered uncertain. In 42 Ethiopian districts, and all 10 of the Tanzanian districts, the number of antigenemic children was below the critical cutoff, suggesting that these districts do not require MDA. Only three Ethiopian districts exceeded the critical cutoff of positive results. Whereas the current World Health Organization guidelines would have recommended MDA in all 55 districts, the present results suggest that only three of these districts requires MDA. By avoiding unnecessary MDA in 52 districts, the confirmatory mapping strategy is estimated to have saved a total of $9,293,219. Public Library of Science 2017-10-04 /pmc/articles/PMC5643143/ /pubmed/28976981 http://dx.doi.org/10.1371/journal.pntd.0005944 Text en © 2017 Gass et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gass, Katherine M.
Sime, Heven
Mwingira, Upendo J.
Nshala, Andreas
Chikawe, Maria
Pelletreau, Sonia
Barbre, Kira A.
Deming, Michael S.
Rebollo, Maria P.
The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania
title The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania
title_full The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania
title_fullStr The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania
title_full_unstemmed The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania
title_short The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania
title_sort rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: examples from ethiopia and tanzania
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643143/
https://www.ncbi.nlm.nih.gov/pubmed/28976981
http://dx.doi.org/10.1371/journal.pntd.0005944
work_keys_str_mv AT gasskatherinem therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT simeheven therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT mwingiraupendoj therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT nshalaandreas therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT chikawemaria therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT pelletreausonia therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT barbrekiraa therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT demingmichaels therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT rebollomariap therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT gasskatherinem rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT simeheven rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT mwingiraupendoj rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT nshalaandreas rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT chikawemaria rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT pelletreausonia rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT barbrekiraa rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT demingmichaels rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania
AT rebollomariap rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania